July 2017 FDA Recall Drug by Pd-rx Pharmaceuticals, Inc.
D-1057-2017 - Failed Tablet/Capsule Specification
This Class II drug recall was voluntarily initiated by Pd-rx Pharmaceuticals, Inc. on July 28, 2017 for the product Drug. The FDA reported the reason for recall as failed tablet/capsule specification. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1057-2017
Failed Tablet/Capsule Specification: out of specification for tablet weight.
07-28-2017
08-09-2017
100 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
PD-Rx Pharmaceuticals, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
E-Mail
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide
12-06-2017
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Famotidine USP 20 mg, 30 tablets bottle, Rx, PKG By; PD Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 --- NDC 55289-765-30
Batch or Lot Expiration Information
Lot# Lot: A17F55 Exp. 06/30/2018